<DOC>
	<DOC>NCT00315055</DOC>
	<brief_summary>To demonstrate that the immune response to hepatitis B antigen of the DTaP-IPV-Hep B-PRP~T is non-inferior to that of the association of PENTAXIM™ and ENGERIX B® one month after a three dose (2-3-4 month) primary series. Immunogenicity - To assess pre- and post-primary series - To assess pre- and post-booster series.</brief_summary>
	<brief_title>Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Twomonth old infants of either gender on the day of inclusion Born at full term of pregnancy (&gt;=37 weeks) with a birth weight &gt;=2.5 kg Informed consent form signed by the parent(s) or other legal representative(s) and an institution official other than an investigator Able to attend all scheduled visits and to comply with all trial procedures. Participation in another clinical trial in the 4 weeks preceding the first trial vaccination Planned participation in another clinical trial during the present trial period Congenital or acquired immunodeficiency, immunosuppressive therapy such as longterm systemic corticosteroid therapy Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to a vaccine containing the same substances Chronic illness at a stage that could interfere with trial conduct or completion Blood or bloodderived products received since birth Any vaccination (except BCG) in the 4 weeks preceding the first trial vaccination Vaccination planned in the 4 weeks following trial vaccination History of documented pertussis, tetanus, diphtheria, polio, Haemophilus influenzae type b or hepatitis B infection(s) (confirmed either clinically, serologically or microbiologically) Known personal or maternal history of HIV, Hepatitis B or Hepatitis C seropositivity Previous vaccination against pertussis, tetanus, diphtheria, polio or Hib, and HB infection(s) Coagulopathy, thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination History of seizures Febrile (axillary temperature 37.4°C [rectal equivalent temperature &gt;=38.0°C]) or acute illness on the day of inclusion.</criteria>
	<gender>All</gender>
	<minimum_age>50 Days</minimum_age>
	<maximum_age>71 Days</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Polio</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Pertussis</keyword>
	<keyword>H influenzae type b</keyword>
</DOC>